Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation TherapyBHOOPALAM, Nirmala; CAMPBELL, Steven C; GAREWAL, Harinder et al.The Journal of urology. 2009, Vol 182, Num 5, pp 2257-2264, issn 0022-5347, 8 p.Article

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032SMITH, David C; TANGEN, Cathy M; VAN VELDHUIZEN, Peter J et al.Urology (Ridgewood, NJ). 2011, Vol 77, Num 5, pp 1172-1176, issn 0090-4295, 5 p.Article

Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate CancerGOLDKORN, Amir; ELY, Benjamin; MONK, J. Paul et al.Journal of clinical oncology. 2014, Vol 32, Num 11, pp 1136-1142, issn 0732-183X, 7 p.Article

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNT0328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate CancerDORFF, Tanya B; GOLDMAN, Bryan; PINSKI, Jacek K et al.Clinical cancer research (Print). 2010, Vol 16, Num 11, pp 3028-3034, issn 1078-0432, 7 p.Article

A phase II study of flavopiridol in patients with advanced renal cell carcinoma : results of Southwest Oncology Group Trial 0109VAN VELDHUIZEN, Peter J; FAULKNER, James R; LARA, Primo N et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 1, pp 39-45, issn 0344-5704, 7 p.Article